All posts by medical

The Death of Wolverine Really DID Kill Logan in Marvel Canon – Screen Rant

When Wolverine died and returned to life a few years later, some suspected that he simply healed himself. But Logan was actually, truly dead.

Comic book characters in general are notorious for dying and coming back to life, but Wolverine is a special case. With his healing factor, its essentially impossible for Logan to actually die - even when his entire skeleton is torn out of him - which made people skeptical of his supposed demise in theDeath of Wolverine series. But believe it or not, that was one instance where Wolverine did, in fact, die.

InDeath of Wolverine, a four-part series published in 2014, Logans healing factor suddenly stops working after he is exposed to a virus from the microverse. Since Wolverines entire physiology is based on the fact that he can heal himself, this was a pretty big problem. Even using his claws was now dangerous, since his hands could no longer heal right away after retracting them. Despite this, Logan refuses to try to find a cure.

Related: How Wolverine Brought Charlie Brown To Marvel's Universe

Soon after, a bounty is put on Wolverine's head, and he decides to track down whoever is after him. It turns out to be Doctor Abraham Cornelius, the founder of the Weapon X program that gave Wolverine his adamantium-covered skeleton. Cornelius has been trying to recreate the experiment performed on Wolverine all those years ago, but it cant be done without Logans healing factor, which he hopes to replicate. Wolverine proceeds to cut his hand and show Cornelius that his healing factor is gone. Enraged, Cornelius forces Wolverine to fight one of his test subjects. Logan wins, but in the process covers himself in liquid adamantium, which proceeds to harden around his body and suffocate him.

Fortunately, the admantium cocoon would not be Logans final resting place. The one-shot Hunt for Wolverine in 2018 revealed that Logan had somehow escaped his seemingly unbreakable tomb, but exactly how was not explained until the Return of Wolverine miniseries later that year.

As it turns out, this was not a case of Wolverines healing factor simply keeping alive for all that time. Logan was actually dead, and his return was only possible through a mutant called Persephone, who has the power to resurrect people. Usually, those she resurrects come back as her mindless, zombie-like servants, but Wolverine managed to remember who he was over time, perhaps due to his healing factor returning as a result of his resurrection. He tells Persephone, Im back and Im Wolverine and thats the way it's gonna be. Classic Logan.

The plot for Death of Wolverine has quite a few similarities to James Mangolds two Wolverine movies, The Wolverine from 2013 and Logan from 2017. The Wolverine also saw Logan lose his healing factor - though he regained it by the end - and the character famously died at the end of Logan as Hugh Jackmans final outing as the character, who he played for almost twenty years. While Jackman has insisted hes hung up the claws for good, the Return of Wolverine could serve as a template for his comeback if he has a change of heart.

More: Why Hugh Jackman Never Wore Wolverine's Mask

How She-Hulk Originally Got Her Powers in Marvel Comics

Eddie is a recent graduate of Skidmore College. He has written for publications such as Silverpen Productions, PreLaw Land, and Clifton Park Neighbors Magazine. Now, he is very excited to be writing for Screen Rant. His hobbies include creative writing, reading, gaming, and constantly re-watching the Marvel movies.

Read more:
The Death of Wolverine Really DID Kill Logan in Marvel Canon - Screen Rant

Exclusive: Nearly 600 And Counting US Health Workers Have Died Of COVID-19 – Kaiser Health News

Nearly 600 front-line health care workers appear to have died of COVID-19, according to Lost on the Frontline, a project launched by The Guardian and KHN that aims to count, verify and memorialize every health care worker who dies during the pandemic.

The tally includes doctors, nurses and paramedics, as well as crucial health care support staff such as hospital janitors, administrators and nursing home workers, who have put their own lives at risk during the pandemic to help care for others. Lost on the Frontline has now published the names and obituaries for more than 100 workers.

A majority of those documented were identified as people of color, mostly African American and Asian/Pacific Islander. Profiles of more victims, and an updated count, will be added to our news sites twice weekly going forward.

There is no other comprehensive accounting of U.S. health care workers deaths. The Centers for Disease Control and Prevention has counted 368 COVID deaths among health care workers, but acknowledges its tally is an undercount. The CDC does not identify individuals.

The Guardian and KHN are building an interactive, public-facing database that will also track factors such as race and ethnicity, age, profession, location and whether the workers had adequate access to protective gear. The database to be released this summer will offer insight into the workings and failings of the U.S. health care system during the pandemic.

In addition to tracking deaths, Lost on the Frontline reports on the challenges health care workers are facing during the pandemic. Many were forced to reuse masks countless times amid widespread equipment shortages. Others had only trash bags for protection. Some deaths have been met with employers silence or denials that they were infected at work.

The number released today reflects the 586 names currently in the Lost on the Frontline internal database, which have been collected from family members, friends and colleagues of the deceased, health workers unions, media reports, unions, among other sources. Reporters at KHN and The Guardian are independently confirming each death by contacting family members, employers, medical examiners and others before publishing names and obituaries on our sites. More than a dozen journalists across two newsrooms as well as student journalists are involved in the project.

Many of the health care workers included here studied physiology and anatomy for years. They steeled themselves against the long hours theyd endure. Emergency medical technicians raced by ambulance to help. Others did the cleanup, maintenance, security or transportation jobs needed to keep operations running smoothly.

They undertook their work with passion and dedication. They were also beloved spouses, parents, friends, military veterans and community activists.

None started 2020 knowing that simply showing up to work would expose them to a virus that would kill them.

This project aims to capture the human stories, compassion and heroism behind the statistics. Among those lost were Dr. Priya Khanna, a nephrologist, who continued to review her patients charts until she was put on a ventilator. Her father, a retired surgeon, succumbed to the disease just days after his daughter.

Susana Pabatao, one of thousands of Philippine health providers in the United States, became a nurse in her late 40s. Susana died just days after her husband, Alfredo, who was also infected with COVID-19.

Dr. James Goodrich, a renowned pediatric neurosurgeon, acclaimed for separating conjoined twins, was also remembered as a renaissance man who collected antique medical books, loved fine wines and played the didgeridoo.

Some of the first to die faced troubling conditions at work. Rose Harrison, 60, a registered nurse, wore no mask while taking care of a COVID-19 patient at an Alabama nursing home, according to her daughter. She felt pressured to work until the day she was hospitalized. The nursing home did not respond to requests for comment.

Thomas Soto, 59, a Brooklyn radiology clerk faced delays in accessing protective gear, including a mask, even as the hospital where he worked was overwhelmed with COVID-19 patients, his son said. The hospital did not respond to requests for comment.

The Lost on the Frontline team is documenting other worrying trends. Health care workers across the U.S. said failures in communication left them unaware they were working alongside people infected with the virus. And occupational safety experts raised alarms about CDC guidance permitting workers treating COVID patients to wear surgical masks which are far less protective than N95 masks.

The Occupational Safety and Health Administration, the federal agency responsible for protecting workers, has launched dozens of fatality investigations into health workers deaths. But recent agency memos raise doubts that many employers will be held responsible for negligence.

As public health guidelines have largely prevented traditional gatherings of mourners, survivors have found new ways to honor the dead: In Manhattan, a medical resident played a violin tribute for a fallen co-worker; a nurses union placed 88 pairs of shoes outside the White House commemorating those who had died among their ranks; fire departments have lined up trucks for funeral processions and held last call ceremonies for EMTs.

The Lost on the Frontline death toll includes only health care workers who were potentially exposed while caring for or supporting COVID-19 patients. It does not, for example, include retired doctors who died from the virus but were not working during the pandemic.

The number of reported deaths is expected to grow. But as reporters work to confirm each case, individual deaths may not meet our criteria for inclusion and, therefore, may be removed from our count.

You can read our first 100 profiles here. And if you know of a health care worker who died of COVID-19, please share their story with us.

See the article here:
Exclusive: Nearly 600 And Counting US Health Workers Have Died Of COVID-19 - Kaiser Health News

In Peoria, clinical trials and a new medicine are bringing hope to the sickest COVID-19 patients – News-Press Now

PEORIA -- Immunology researcher Dr. Joseph Kim switched his focus from organ rejection to COVID-19 in the last few months.

Since coming to Peoria in 2018, Kim had been working with OSF HealthCare Saint Francis Medical Center's organ transplant team to develop better treatments for organ rejection, but COVID-19 has brought him a new challenge.

As an infectious disease specialist, Kim is part of the team treating COVID-19 patients at St. Francis. As part of that work, he is gathering information for a clinical trial on a COVID-19 drug in development by I-Mab Biopharma. St. Francis is one of several hospitals across the country participating in the clinical trial to determine if the drug, currently known as TJ003234, is a safe and effective treatment for COVID-19. The drug is designed to treat the cytokine storm some patients suffer when their immune system overreacts to the virus.

"I'm sure you've heard in the news that some people have a lot of consequences from being sick with the virus: shock, acute respiratory distress, blood clots -- these are different things that happen after infection that may be related to the body's own response against the virus," said Kim. "So what's been shown is that people that have serious infection, their body's own immune response can be very dysregulated, it can be very exaggerated, and that can actually cause harm to the body."

TJ003234 works in a similar way as Tocilizumab, a more widely known drug already FDA approved to treat rheumatoid arthritis. Tocilizumab is also in clinical trials at other hospitals around the U.S. to test its efficacy for the treatment of COVID-19 patients. One of the things researchers are keeping a close eye on is side effects.

"If you are using something that's trying to counteract someone's immune response, some of the unintended consequences could be infection, because you obviously need your immune response to function well to fight off infection," said Kim. "So that's a big concern. So that's why these things need to be studied, obviously."

Clinical trials like this are happening all over the world in the race to come up with an effective treatment for COVID-19. Hospitals are enrolling in trials not only to help researchers, but also to be able to provide some hope for patients and their families for a virus that currently has no known treatments.

"So that's what we've been focusing on at OSF, getting in trials that allow us to give treatments to patients that are very, very sick that wouldn't be available otherwise," said Kim.

The trial, which began in mid-April, is in an early stage, where just a few patients have been given the drug to make sure it is safe, said Kim. Once safety is determined, it will be administered to more patients, and results will be recorded to determine if it is helping. Since it is a double-blind trial, with one group getting the drug and another getting a placebo, Kim and other researchers won't know the results until all the data is gathered.

The clinical trial is one of two COVID-19 trials being done at St. Francis. It is also participating in a clinical trial headed by Mayo Clinic on convalescent plasma, anti-body rich blood plasma gathered from recovered COVID-19 patients.

"Your body makes antibodies, and those antibodies can be protective against that virus," said Kim. "So basically what you are trying to do is taking the antibodies that are protective and give them to someone who doesn't have them yet, someone whose body is not making effective antibodies."

The convalescent plasma study is not a blind study, and last month researchers announced that a couple patients who had received the plasma were recovering. But as yet, those happy results are only anecdotal -- researchers are not yet ready to say if convalescent plasma is truly helpful in the treatment of COVID-19.

"With all these studies, you can't draw firm conclusions with such a small sample size and one physician's experience with a patient," said Kim. "That's the problem, and that's what's so hard about being able to treat patients and navigate through this pandemic -- we don't have this type of data yet. For other infections, like influenza, we have different treatments and vaccines. Influenza has definitely been studied well, so we can be confident about the effectiveness of what we are doing. It's just unfortunate that it's just not like that for COVID-19."

Another treatment doctors at St. Francis are using is Remdesevir. Because it has already been studied and has shown enough promise that the FDA gave it emergency-use approval, hospitals don't have to enroll in a clinical trial to get the drug.

"We've used it in Peoria on three patients so far," said infectious disease specialist Dr. Douglas Kasper, a faculty member at the University of Illinois College of Medicine Peoria. "Remdesevir can be used as an antiviral agent, with the idea that you are arresting viral replication as early as possible."

Though it has shown some promise in one study, doctors are still evaluating its worth as a treatment, said Kasper. Another issue with Remdesevir is that it is in very short supply. Area hospitals have only been given enough to treat a few patients.

All research is contingent on need, and no one knows what the need will be for COVID-19 treatments going forward.

"To do a clinical trial, you have to have sick people, otherwise you don't have anyone to enroll in the trial," said Kasper. "As the summer goes, and if our rates continue to go down, we won't make progress because we won't have anyone to enroll. That is kind of what happened with the first SARS virus. It was circulating mostly in Asia, causing terrible effects, and there was a huge response into the development of therapeutics and a vaccine. Towards the end of that outbreak, the virus mutated and became weaker, and clinical effects on people were less -- people didn't go to hospital and didn't die, then drive from industry became less. Could that happen with COVID-19? It could, but it's not something you could bet on. We don't know. That's the part of this that is so interesting -- each day, every week, it changes so much. To be able to match all this up and plan is quite a process."

Continue reading here:
In Peoria, clinical trials and a new medicine are bringing hope to the sickest COVID-19 patients - News-Press Now

Are we underestimating how many people are resistant to Covid-19? – The Guardian

During the first wave of the Covid-19 pandemic, cities were in general affected worse than smaller conurbations or rural areas. Yet in Italy, Rome was relatively spared while the villages of Lombardy experienced very high rates of sickness and death. Then again, one Lombard village Ferrara Erbognone stood out for not recording a single case of Covid-19 at the height of the wave. Nobody knows why.

The puzzle is not just Italian. From the beginning, Covid-19 struck unevenly across the globe, and scientists have been trying to understand the reasons. Why are some populations or sectors of a population more vulnerable than others? Or to turn the question around, why are some groups relatively protected?

In the Observer last weekend, neuroscientist and Covid-19 modeller Karl Friston of University College London suggested on the basis of his comparison of German and British data that the relatively low fatality rates recorded in Germany were due to unknown protective factors at play. This is like dark matter in the universe: we cant see it, but we know it must be there to account for what we can see, he said.

While this is a novel view most experts praise Germanys lockdown and systematic testing regime others are working hard to identify factors which are modulating the spread of Covid-19 and in doing so could explain other puzzles such as why Japan seems to have avoided a lethal first wave despite its relatively old population and lacklustre public health response, or why Denmark, Austria and the Czech Republic have reported no surge in cases despite their early easing of lockdown measures. That could shape how governments manage the risks of a second wave.

One thing seems clear: there are many reasons why one population is more protected than another. Theoretical epidemiologist Sunetra Gupta of the University of Oxford thinks that a key one is immunity that was built up prior to this pandemic. Its been my hunch for a very long time that there is a lot of cross-protection from severe disease and death conferred by other circulating, related bugs, she says. Though that cross-protection may not protect a person from infection in the first place, it could ensure they only experience relatively mild symptoms.

Guptas hunch has remained just that, because of the lack of data on immunity to Covid-19. Antibody testing, as we know, was slow to get going and unreliable to begin with, and the results to date suggest that the proportions of populations carrying antibodies to the Covid-19 virus are often in single or low-double digits. New, more sensitive antibody tests that have become available in recent weeks could soon provide a much more accurate picture if deployed widely enough, but there are already hints that the results to date may be underestimates.

First there was evidence based on diagnostic testing of postmortem samples from patients who died in December that the virus was circulating in western countries notably France and the US about a month earlier than was initially thought. New research shows that another component of the human immune response T cells, which help orchestrate the antibody response show memory for coronavirus infection when exposed to Sars-CoV-2, the virus that causes Covid-19.

In a paper published in Cell on 14 May, researchers at the La Jolla Institute for Immunology in California reported that T cells in blood drawn from people between 2015 and 2018 recognised and reacted to fragments of the Sars-CoV-2 virus. These people could not have possibly seen Sars-CoV-2, says one of the papers senior authors, Alessandro Sette. The most reasonable hypothesis is that this reactivity is really cross-reactivity with the cousins of Sars-CoV-2 the common cold coronaviruses which circulate very broadly and generally give rather mild disease.

The finding supported an earlier one from a group at the Charit hospital in Berlin, detecting T cell reactivity to proteins in the Sars-CoV-2 virus in 83% of Covid-19 patients but also in 34% of healthy volunteers who had tested negative for the virus itself.

David Heymann, an epidemiologist at the London School of Hygiene and Tropical Medicine who advises the World Health Organization on Covid-19, says these results are important, but cautions that cross-reactivity doesnt necessarily translate into immunity. To determine whether it does would involve following a large number of people who show such cross-reactivity to see if they are protected, if not from infection with Covid-19, then at least from severe forms of the disease.

It is, however, a reasonable hypothesis that exposure to other coronaviruses could confer protection, Sette says. Weve seen it before, for example with the 2009 H1N1 flu. Older people fared well compared to other age groups in that pandemic, he says, probably because their immune systems had been primed by exposure to similar flu strains from decades before. That could be the reason the 2009 pandemic was less lethal than other flu pandemics in history, killing an estimated 200,000 people globally.

If exposure to other coronaviruses does protect against Covid-19, Gupta says, then variability in that exposure could explain much of the difference in fatality rates between countries or regions. Exposure to the related virus that caused the epidemic of severe acute respiratory syndrome (Sars) in 2002-4 might have afforded some protection to east Asians against Covid-19, for example.

In late March, Guptas group published a paper that drew attention because it generated very different forecasts from those of epidemiologist Neil Ferguson of Imperial College London and his colleagues to whom the UK government was listening most closely. The Oxford group suggested that up to half of the UK population could already have been infected by Sars-CoV-2, meaning the infection fatality rate (IFR) the proportion of infected people who went on to die was much lower than Fergusons group was indicating, and the disease was therefore less dangerous. Neither group had much data at that point, and Gupta says that her intention was to highlight that, in the absence of data, a wide range of scenarios should be considered.

Two months on, she stands by her model, but wishes that she had made its implications clearer. The truth is that the IFR is not a hardwired property of the virus or of our interaction with the virus, she says. Its the vulnerable fraction [of the population] that is determining the average overall risk of dying. Once an elderly care home is infiltrated by the virus, for example, the virus spreads rapidly through it and is often lethal, pushing up the IFR. This means it is critical to understand why some people are resistant and others are not, so that those who are vulnerable can be protected.

We know some of those vulnerability factors. Age is the most obvious one. Unlike with the 2009 flu, elderly people are particularly vulnerable to Covid-19 a fact that might reflect the history of exposure to coronaviruses of different age cohorts. Comorbidity is another, and a third is being male. According to Garima Sharma of Johns Hopkins University School of Medicine in Baltimore, who with colleagues recently published a paper on sex differences in Covid-19 mortality, women are protected by virtue of having a backup X chromosome. X chromosomes contain a high density of immune-related genes, so women generally mount stronger immune responses, she says.

Socioeconomic status, climate, culture and genetic makeup could also shape vulnerability, as could certain childhood vaccines and vitamin D levels. And all of these factors can vary between countries. The Japanese might have been afforded some protection, for example, by their custom of bowing rather than shaking hands. And though most of the disparity between the sexes is down to biology, Sharma says some of it is due to social and behavioural factors, with women being more likely to wash their hands and seek preventive care.

It is also becoming clear that protecting the vulnerable has made a big difference to outcomes so far. Italy and Germany, for example, have similar proportions of over-65-year-olds just over 20% of the population in both cases and yet the two have reported strikingly different fatality rates. The case fatality rate (CFR) the proportion of the sick who go on to die is less informative but easier to measure than the IFR, because sick people are more visible than merely infected ones, and as at 26 May the CFR in Italy was about 14%, compared to 5% in Germany.

Italy is more densely populated than Germany, and Italian homes tend to be smaller than German ones. Many Italians in their 20s and 30s live at home with their extended families, which meant that transmission to the elderly was high and, when critical care units were overwhelmed, so were deaths. This is rarer in Germany, where many elderly care homes also enacted a strict isolation regime. In Germany, says Heymann, they did a better job in keeping the elderly protected. Some estimates suggest that only 20% of German Covid-19 cases were over 60, as compared to more than 90% in Italy.

The UK, which has recorded the second highest death rate from Covid-19 after Spain, has not looked after its elderly so well deciding at one point to discharge patients from hospitals back to care homes without testing them for the disease. The governments advice to 1.5 million UK citizens with underlying health conditions to self-isolate for three months from late March may have helped protect those people, but for Gupta the UKs high death rate reflects a deeper problem years of erosion of community support services that provided pastoral care. There is just not enough investment in the NHS and in that GP or other frontline individual who advises the vulnerable person, she says.

Holding to her hunch, she believes that lockdown was an overreaction and that frontline care and protection of the vulnerable which should have been a priority from the beginning should be prioritised now. She also thinks that the worst is behind us, and that while subsequent waves cant be ruled out, they will probably be less bad than what we have experienced so far. The disease will settle into an endemic equilibrium, in her view, perhaps returning each winter like a seasonal flu.

Fristons models also suggest that immunity in the population is higher than data indicates, but for him its not clear how long that immunity will last and he argues that test-and-trace protocols should be put in place now, ahead of any possible second wave that might erupt once that immunity drops off. Heymann remains wary of models, which he says have too often been mistaken for reality in this pandemic, and he awaits more data: I dont think anybody can predict the destiny of this virus at this point in time, he says.

Continue reading here:
Are we underestimating how many people are resistant to Covid-19? - The Guardian

Biomarkers of Exacerbation in Severe Asthma – Pulmonology Advisor

High counts of blood eosinophils combined with increased fractional exhaled nitric oxide (FeNO) may serve as biomarkers for a risk for exacerbations in patients with severe asthma, according to study results published in the Journal of Allergy and Clinical Immunology: In Practice.

With this 52-week, prospective, single-arm, longitudinal, noninterventional, multicenter ARIETTA study (ClinicalTrials.gov identifier: NCT02537691) conducted in real-world patients with severe asthma, investigators sought to evaluate the ability of type 2 biomarkers to predict severe outcomes. The primary study endpoint was the asthma exacerbation rate over 52 weeks in serum periostin-high (50 ng/mL at baseline) vs serum periostin-low (<50 ng/mL at baseline) subgroups.

The total number of exacerbations observed over 52 weeks divided by the total patient-weeks was used to estimate the unadjusted exacerbation rate. Secondary study outcomes were: the percentage of patients with treatment failure; the percentage of participants with changes in standard-of care treatments that were considered to be clinically meaningful; the time to initial asthma exacerbation; the time to treatment failure; the change from baseline in FeNO levels; the change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV1); the change from baseline in patient-reported quality of life; and safety over 52 weeks in periostin-high and -low subgroups.

A total of 465 adult patients (median patient age, 54 years; range, 17-83 years; 66.5% women) from 84 sites in 13 countries with severe asthma were enrolled. Participants were receiving daily inhaled corticosteroids (fluticasone propionate 500 g or equivalent) and 1 second controller medication. Biomarker, clinical, and safety data were collected from all of the participants over 52 weeks.

The median time since a diagnosis of asthma was 19.4 years. In the prior year, 42.4% of patients had experienced 1 asthma exacerbation. At baseline, 52.0% of patients were periostin-high and 48.0% of participants were periostin-low. Overall, 87.5% of participants had type 2 inflammation (ie, blood eosinophils 150 cells/L and/or FeNO 25 ppb, and/or positive skin allergen test).

Biomarker levels were found to correlate poorly with each other. Central and local laboratory blood eosinophil and immunoglobulin E measurements, however, were generally in agreement. There was no significant difference reported in asthma exacerbation rates over 52 weeks between periostin-high and periostin-low subgroups (rate ratio, 0.93; 95% CI, 0.67 to 1.28; P =.642). Higher exacerbation rates were observed in participants with blood eosinophils 300 cells/L and FeNO 25 ppb.

[T]here were no clinically meaningful differences in the exacerbation rates between periostin-high and periostin-low subpopulations of patients with severe asthma in this study. Key Type 2 biomarkers, including periostin, blood eosinophils, serum IgE, and FeNO, were not highly correlated with each other, concluded the study authors. [P]ost hoc exploratory analyses suggested a potential clinically relevant predictive and prognostic ability for asthma exacerbation of blood eosinophils and FeNO when used in combination.

Reference

Buhl R, Korn S, Menzies-Gow A, et al. Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma [published online April 15, 2020]. J Allergy Clin Immunol Pract. pii: S2213-2198(20)30338-X. doi: 10.1016/j.jaip.2020.03.038

Read the rest here:
Biomarkers of Exacerbation in Severe Asthma - Pulmonology Advisor

Covid-19: ‘We have to assume the virus has attenuated’ – RNZ

Covid-19 has likely become less potent as it mutates over time, and hopefully one day will become a common cold virus, a New Zealand, London-based professor says.

Photo: Unsplash / Kvin et Laurianne Langlais

Professor Alberto Zangrillo, head of intensive care at Italy's San Raffaele Hospital in Lombardy, says the new coronavirus is losing its potency and has become much less lethal. He told state television the new coronavirus "clinically no longer exists".

But World Health Organisation experts and a range of other scientists said there was no evidence to support his claim.

There is no data to show the new coronavirus is changing significantly, either in its form of transmission or in the severity of the disease it causes, they said.

But New Zealander Gary McLean, a professor in molecular immunology at London Metropolitan University, told Sunday Morning he was inclined to believe Zangrillo, whose claim was backed up by a second doctor from northern Italy who said he was also seeing the coronavirus weaken.

"They've experienced the full gamut of this virus and the effects and I think we have to believe what they're saying, the clinical picture that is. If they're seeing reduced severity there must be something to it.

"It's really difficult to know why exactly at this point, because there's a lot of reasons why it could be and there's no scientific literature, peer-reviewed papers that really document this, but if the clinicians are saying that I have to think it's probably real."

The virus may well have changed or attenuated causing a change in the clinical picture, McLean said.

"I would probably favour that in some way the virus is attenuating itself, just by accumulating mutations over timeand these little mutations accumulate and eventually the virus has had long enough in that host, in humans, it will drift and change slightly," McLean said.

Zangrillo, well known in Italy as the personal doctor of former Prime Minister Silvio Berlusconi, said his comments were backed up by a study conducted by a fellow scientist, Massimo Clementi, which Zangrillo said would be published soon.

Zangrillo said: "We have never said that the virus has changed, we said that the interaction between the virus and the host has definitely changed."

He said this could be due either to different characteristics of the virus, which he said they had not yet identified, or different characteristics in those infected.

The study by Clementi, who is director of the microbiology and virology laboratory of San Raffaele, compared virus samples from Covid-19 patients at the Milan-based hospital in March with samples from patients with the disease in May.

"The result was unambiguous: an extremely significant difference between the viral load of patients admitted in March compared to" those admitted last month, Zangrillo said.

Oscar MacLean of the University of Glasgow's Centre for Virus Research said suggestions that the virus was weakening were "not supported by anything in the scientific literature and also seem fairly implausible on genetic grounds."

Experts and representatives of Johns Hopkins University, Wake Forest Baptist Medical Center, George Washington University and Northwell Health also said they were not aware of evidence suggesting that the virus had changed.

Could Covid-19 become a common cold?

Gary McLean said there were 40 known coronaviruses, including seven which have infected humans, including four which are endemic cold viruses which cause relatively mild symptoms.

"One could argue originally those four might have been similar to SARS1, MERS and SARS2, and they attenuated themselves and became just a mild common cold."

One of the endemic strains, OC43, has been mapped back in time and the common ancestor is a cow coronavirus thought to have jumped into humans in 1890, McLean said.

"And coincidentally in 1890 there was a world-wide pandemic of a respiratory disease that killed one million people. And you can put one and one together and assume OC43 may have come from a pandemic and over the next 130 years it's evolved into a very mild, common cold virus," McLean said.

"And I'm hoping it doesn't take 130 years for this one to get that mild, but let's say it might take a year or so and we're going to have another common cold coronavirus.

"So I'd like to predict that but I don't know for sure if that will happen."

- Reuters/ RNZ

Continued here:
Covid-19: 'We have to assume the virus has attenuated' - RNZ

The anatomy of a pandemic – BBC News

South Korea, a nation of 51 million people, stands out as one of the most successful countries in the world in managing to contain Covid-19.

Much of this success has been attributed to the countrys ability to mobilise a small army of contact tracers: detectives trained to connect the dots between a positive Covid-19 case and all their most recent contacts. The tracers must then decide who should be instructed to self-isolate, or, in some cases, whether to quarantine an entire building or organisation, such as a hospital, care home or office.

New daily cases of Covid-19 in South Korea

New daily cases of Covid-19 in South Korea

With only a handful of cases throughout January and early February, many South Koreans thought perhaps a large outbreak had been avoided. However, in late February, from a single city, came a sudden escalation of thousands of cases reported within the space of only a few days.

The outbreak in Daegu city has since been attributed to the movements of one single person, South Koreas superspreader - the now infamous patient 31.

The city of Daegu accounts for more than 60% of all of the country's cases

The city of Daegu accounts for more than 60% of all of the country's cases

Patient 31 tested positive for coronavirus on 17 February. It was only thanks to the work of contract tracers, that all her most recent contacts - which, shockingly, turned out to be more than 1,000 people in the space of 10 days - were tracked down and instructed to self-isolate, thus avoiding an even bigger outbreak.

As deputy of Daegus epidemiology team, Professor Kim Jong-Yeon is responsible for the citys infantry of contact tracers - often former government employees, as well as junior doctors. He says only if people are evasive, do they use more rigorous methods - such as investigating their credit card transactions and their phone or GPS history. People such as patient 31.

Professor Kim Jong-Yeon in Daegu City

Professor Kim Jong-Yeon in Daegu City

Patient 31, at first she didn't tell us she was from the Shincheonji Church. It was us, the contact tracers, who later discovered she was a member, says Prof Kim.

With approximately 300,000 members nationwide, the doctrine of Shincheonji Church of Jesus claims their founder, Lee Man-hee, is the second coming of Jesus Christ and that only he can interpret the Bible. Many mainstream Christian churches in South Korea consider the group to be a cult and have long criticised their aggressive recruitment of young people.

A service at Shincheonji Gyeonggi-doChurch. Source: Shincheonji

A service at Shincheonji Gyeonggi-doChurch. Source: Shincheonji

But patient 31 has not become infamous simply for covering up her affiliation with Shincheonji Church. As contact tracers uncovered, in the 10 days prior to being tested - despite showing symptoms - she travelled around the city of Daegu coming into contact with more than 1,000 people.

After being involved in a car accident on 6 February, patient 31 was admitted to hospital on 7 February, where she came into close contact with an estimated 128 people. She then temporarily discharged herself in order to return home to collect personal belongings, a two-and-a-half-hour round-trip, before returning to hospital. Later that week she discharged herself multiple times, once going for lunch with a friend, and twice in order to attend a a two-hour church service with a 1000-strong congregation.

Due to the secretive nature of the Shincheonji Church, Prof Kim says the hardest part of the investigation was trying to establish who also visited the church during that week.

We finally secured a list of all 9,000 members of the church. At first, we started to call and ask all of them if they had any symptoms. About 1200 people told us they did, but some people refused to get tested and self-quarantine.

With hundreds of individuals reluctant to reveal their association with the secretive church, the professor says they were left with no choice.

It became a matter of how quickly we could separate those church members from the rest of Daegus citizens. So the government issued an executive order for all church members to self-isolate.

Thousands of students of the Shincheonji Church celebrate their in-house graduation. Source: Shincheonji

Thousands of students of the Shincheonji Church celebrate their in-house graduation. Source: Shincheonji

The citys rigorous investigation of all new cases, combined with comprehensive testing, quickly curbed the spread of the virus - and by early April, the city of Daegu reported zero new cases of Covid-19.

However, elsewhere in the world, the virus continued to advance unabated. For the scientific community, it became vital to track the virus, not only over borders, but across continents.

The answer to this problem lay in the genome, clues left behind in the genetic code of the virus as it began to replicate and spread.

View post:
The anatomy of a pandemic - BBC News

Introducing the Anatomage Table Companion App To Visualize Real Human Anatomy with an iPad – PRNewswire

Anatomage created the Anatomage Table Companion App to bring the world's most accurate digital cadaver to the iPad. All of the functionality and content is derived from the award-winning Anatomage Table platform. The Anatomage Table Companion app will introduce a real male cadaver with the functionality and content highlighted below:

Anatomage Table Companion is designed to complement the utilization of the Anatomage Table. The app is a solution to aid Table users who are unable to access their physical Table. By allowing Table users to review anatomy concepts at home, the app supplements in-class lessons that are incorporated with the Anatomage Table. Anatomage Table Companion provides essential anatomy knowledge for all medical disciplines.

For more information about the app, please visit here.

About Anatomage

A market leader in medical imaging technology, Anatomage enables an ecosystem of 3D anatomy hardware and software, allowing users to visualize anatomy at the highest level of accuracy. Through its highly innovative products, Anatomage is transforming standard anatomy learning, medical diagnosis and treatment planning.

Media Contact:Jack Choi CEO Anatomage Inc. Phone: 1-408-885-1474, Email:[emailprotected]www.anatomage.com

SOURCE Anatomage

Table

See the rest here:
Introducing the Anatomage Table Companion App To Visualize Real Human Anatomy with an iPad - PRNewswire

Shonda Rhimes: 7 Interesting Things To Know About The Grey’s Anatomy Creator – CinemaBlend

Since it was founded in 2005, Shondaland, the name of Shonda Rhimes' production company, has become synonymous with the moving stories that she has brought to television. However, in recent year, it has become synonymous with the moving stories that she has given real people a venue on which to share them. In 2017, Rhimes launched shondaland.com, a lifestyle website that offers tips on health, social living, and cultural awareness through various mediums and is open for contributions from anyone who, like Rhimes, aims to make a difference in the world through inspiration and positive change.

Read the original here:
Shonda Rhimes: 7 Interesting Things To Know About The Grey's Anatomy Creator - CinemaBlend